In our weekly check, Tarsus Pharmaceuticals, Inc. is graded C (A to F). Of 22 checks on debt, profit, cash flow and trend: 12 pass, warnings: 2, red flags: 8.
Sector: Healthcare · Biotechnology
Next earnings report: 2026-11-03
AMLX · DYN · DNLI · RCUS · CELC · ARQT
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-10-10